Immunic Inc

NASDAQ:IMUX   3:59:59 PM EDT
9.17
+0.02 (+0.22%)
Products, Other Pre-Announcement

Immunic, Inc. Announces FDA Clearance To Begin Imu-838 Phase 3 Ensure Studies In Relapsing-Remitting Multiple Sclerosis And Phase 2 Calliper Study In Progressive Multiple Sclerosis

Published: 07/01/2021 10:43 GMT
Immunic Inc (IMUX) - Immunic, Inc. Announces FDA Clearance to Begin Imu-838 Phase 3 Ensure Studies in Relapsing-remitting Multiple Sclerosis and Phase 2 Calliper Study in Progressive Multiple Sclerosis.
Immunic Inc - Expects Initiation of Both Ensure and Calliper in Second Half of 2021.
Immunic Inc - FDA Also Cleared Co's Ind Application for Supportive Phase 2 Calliper Trial of Imu-838 in Patients With Progressive Multiple Sclerosis.